OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the...
OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody lusvertikimab in ulcerative colitis showing a potential improvement in symptom
Boehringer and OSE to advance cancer immunotherapy to clinics
Nantes, France – July 1st, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the publication of an article on latest preclinical efficacy data on the use of its anti-IL-7 receptor (IL-7R
OSE Immunotherapeutics SA announced that the company has entered into a commercial and revenue sharing agreement with Memorial Sloan Kettering Cancer Center (MSK), a leading global cance
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN:...
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disordersat the FOCIS Annual Meeting, San Francisco (June 18 – 21) ...
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth Nantes, France – June 19, 2024,...
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5...
OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months: New strategic partnership with AbbVie for OSE-230, a novel...